Structure-function correlation of the human central retina

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-9

  Issa, Peter Charbel ^a,b   Troeger, Eric ^c   Finger, Robert ^a   Holz, Frank G ^a   Wilke, Robert ^c,d   Scholl, Hendrik P N ^a,e  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MACULAR TELANGIECTASIA TYPE 2; NERVE DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHOTORECEPTOR; PHOTOSENSITIVITY; RETINA MACULOPATHY; RETINAL THICKNESS; STRUCTURE ACTIVITY RELATION; VISUAL SYSTEM PARAMETERS;

EID: 77958452219     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012864     Document Type: Article

References (43)

1. Drexler W, Morgner U, Ghanta RK, Kartner FX, Schuman JS, et al. (2001) Ultrahigh-resolution ophthalmic optical coherence tomography. Nat Med 7: 502-507.
2. Drexler W, Fujimoto JG (2008) State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 27: 45-88.
3. Schmitz-Valckenberg S, Holz FG, Bird AC, Spaide RF (2008) Fundus autofluorescence imaging - Review and perspectives. Retina 28: 385-409.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
6. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, et al. (2009) Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116: 2175-2181.
7. Campochiaro PA (2007) Seeing the light: new insights into the molecular pathogenesis of retinal diseases. J Cell Physiol 213: 348-354.
8. Schlingemann RO, Witmer AN (2009) Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 175: 253-267.
9. Rohrschneider K, Bultmann S, Springer C (2008) Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Prog Retin Eye Res 27: 536-548.
10. Helb HM, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Scholl HPN, et al. (2009) Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol 87: [Epub ahead of print] DOI 10.1111/j.1755-3768.2009.01602.x.
11. Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HPN (2007) Microperimetric assessment of patients with type 2 macular telangiectasia. Invest Ophthalmol Vis Sci 48: 3788-3795.
12. Gaudric A, Ducos de LG, Cohen SY, Massin P, Haouchine B (2006) Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 124: 1410-1419.
13. Paunescu LA, Ko TH, Duker JS, Chan A, Drexler W, et al. (2006) Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology 113: 48-57.
14. Finger RP, Charbel IP, Fimmers R, Holz FG, Rubin GS, et al. (2009) Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci 50: 1366-1370.
15. Gerth C, Zawadzki RJ, Werner JS, Heon E (2008) Retinal morphological changes of patients with X-linked retinoschisis evaluated by Fourier-domain optical coherence tomography. Arch Ophthalmol 126: 807-811.
16. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, et al. (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114: 525-536.
17. Forooghian F, Stetson PF, Meyer SA, Chew EY, Wong WT, et al. (2010) Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina 30: 63-70.
18. Fischer MD, Fleischhauer JC, Gillies MC, Sutter FK, Helbig H, et al. (2008) A new method to monitor visual field defects caused by photoreceptor degeneration by quantitative optical coherence tomography. Invest Ophthalmol Vis Sci 49: 3617-3621.
19. Jacobson SG, Roman AJ, Aleman TS, Sumaroka A, Herrera W, et al. (2010) Normal central retinal function and structure preserved in retinitis pigmentosa. Invest Ophthalmol Vis Sci 51: 1079-1085.
20. Barthelmes D, Sutter FK, Kurz-Levin MM, Bosch MM, Helbig H, et al. (2006) Quantitative analysis of OCT characteristics in patients with achromatopsia and blue-cone monochromatism. Invest Ophthalmol Vis Sci 47: 1161-1166.
21. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53-67.
22. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3: e3554.
23. Bartsch DU, Freeman WR (1994) Axial intensity distribution analysis of the human retina with a confocal scanning laser tomograph. Exp Eye Res 58: 161-173.
24. Zhang YH, Roorda A (2006) Evaluating the lateral resolution of the adaptive optics scanning laser ophthalmoscope. J Biomed Opt 11: 014002.
25. Zawadzki RJ, Jones SM, Olivier SS, Zhao MT, Bower BA, et al. (2005) Adaptive-optics optical coherence tomography for high-resolution and highspeed 3D retinal in vivo imaging. Opt Express 13: 8532-8546.
26. Sincich LC, Zhang Y, Tiruveedhula P, Horton JC, Roorda A (2009) Resolving single cone inputs to visual receptive fields. Nat Neurosci 12: 967-969.
27. Hood DC, Anderson SC, Wall M, Raza AS, Kardon RH (2009) A test of a linear model of glaucomatous structure-function loss reveals sources of variability in retinal nerve fiber and visual field measurements. Invest Ophthalmol Vis Sci 50: 4254-4266.
28. Weber BH, Schrewe H, Molday LL, Gehrig A, White KL, et al. (2002) Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci USA 99: 6222-6227.
29. Zeng Y, Takada Y, Kjellstrom S, Hiriyanna K, Tanikawa A, et al. (2004) RS-1 Gene Delivery to an Adult Rs1h Knockout Mouse Model Restores ERG b-Wave with Reversal of the Electronegative Waveform of X-Linked Retinoschisis. Invest Ophthalmol Vis Sci 45: 3279-3285.
30. Min SH, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, et al. (2005) Prolonged recovery of retinal structure/function after gene therapy in an Rs1hdeficient mouse model of X-linked juvenile retinoschisis. Mol Ther 12: 644-651.
31. Kjellstrom S, Bush RA, Zeng Y, Takada Y, Sieving PA (2007) Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 48: 3837-3845.
32. Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, et al. (2009) Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 16: 916-926.
33. Janssen A, Min SH, Molday LL, Tanimoto N, Seeliger MW, et al. (2008) Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 16: 1010-1017.
34. Sohn EH, Chen FK, Rubin GS, Moore AT, Webster AR, et al. (2010) Macular function assessed by microperimetry in patients with enhanced S-cone syndrome. Ophthalmology 117: 1199-1206.
35. Katz R (2004) Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1: 189-195.
36. Phillips KA, Van BS, Issa AM (2006) Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov 5: 463-469.
37. Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100: 1536-1546.
38. Charbel Issa P, Berendschot TTJM, Staurenghi G, Holz FG, Scholl HPN (2008) Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest OphthalmolVisSci 49: 1172-7.
39. Charbel Issa P, van der Veen RLP, Stijfs A, Holz FG, Scholl HPN, et al. (2009) Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res 89: 25-31.
40. Lee S, Abramoff MD, Reinhardt JM (2007) Feature-based pairwise retinal image registration by radial distortion correction. Proc SPIE Conf Medical Imaging 6512: DOI: 10.1117/12.710676.
41. Barthelmes D, Gillies MC, Sutter FKP (2008) Quantitative OCT analysis of idiopathic perifoveal telangiectasia. Invest Ophthalmol Vis Sci 49: 2156-2162.
42. Crossland MD, Sims M, Galbraith RF, Rubin GS (2004) Evaluation of a new quantitative technique to assess the number and extent of preferred retinal loci in macular disease. Vision Res 44: 1537-1546.
43. Charbel Issa P, Holz FG, Scholl HPN (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114: 1736-1742.